ATE328887T1 - Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen - Google Patents

Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE328887T1
ATE328887T1 AT00900497T AT00900497T ATE328887T1 AT E328887 T1 ATE328887 T1 AT E328887T1 AT 00900497 T AT00900497 T AT 00900497T AT 00900497 T AT00900497 T AT 00900497T AT E328887 T1 ATE328887 T1 AT E328887T1
Authority
AT
Austria
Prior art keywords
treatment
neurodegenerative diseases
heterocyclic compounds
condensed heterocyclic
lesioned
Prior art date
Application number
AT00900497T
Other languages
English (en)
Inventor
Dan Peters
Mette Gronborg
Arne Moller
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE328887T1 publication Critical patent/ATE328887T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00900497T 1999-01-19 2000-01-13 Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen ATE328887T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900061 1999-01-19

Publications (1)

Publication Number Publication Date
ATE328887T1 true ATE328887T1 (de) 2006-06-15

Family

ID=8089290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00900497T ATE328887T1 (de) 1999-01-19 2000-01-13 Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen

Country Status (10)

Country Link
US (1) US6576641B2 (de)
EP (1) EP1147113B1 (de)
JP (1) JP2002535334A (de)
CN (1) CN1147490C (de)
AT (1) ATE328887T1 (de)
AU (1) AU776276B2 (de)
CA (1) CA2353903A1 (de)
DE (1) DE60028538T2 (de)
NZ (1) NZ512289A (de)
WO (1) WO2000043397A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027114A1 (en) 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2395028A2 (fr) * 1977-06-22 1979-01-19 Centre Etd Ind Pharma Derives pyridiniques, leur preparation et leurs application therapeutique
FR2566775B1 (fr) 1984-06-27 1986-10-31 Synthelabo Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique
FR2570701B1 (fr) * 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
FR2635977B1 (fr) * 1988-09-07 1992-05-15 Synthelabo Utilisation de derives de tetrahydro-4,5,6,7 furopyridines pour obtenir des medicaments destines au traitement de l'obesite
GB8921465D0 (en) * 1989-09-22 1989-11-08 Fujisawa Pharmaceutical Co Bicyclic amine compound and a process for the preparation thereof
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CN1160403A (zh) * 1994-10-11 1997-09-24 武田药品工业株式会社 取代杂双环烷基胺和它们作为角鲨烯氧化物环化酶抑制剂的用途
DE69634647T2 (de) * 1995-09-11 2006-03-02 Aventis Pharmaceuticals Inc. Cyclische Nitrone und pharmazeutische Mittel die sie enthalten

Also Published As

Publication number Publication date
DE60028538T2 (de) 2007-06-21
US6576641B2 (en) 2003-06-10
AU776276B2 (en) 2004-09-02
US20020013336A1 (en) 2002-01-31
DE60028538D1 (de) 2006-07-20
NZ512289A (en) 2003-06-30
EP1147113B1 (de) 2006-06-07
JP2002535334A (ja) 2002-10-22
CA2353903A1 (en) 2000-07-27
EP1147113A1 (de) 2001-10-24
CN1147490C (zh) 2004-04-28
WO2000043397A1 (en) 2000-07-27
CN1336929A (zh) 2002-02-20
AU3033300A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE463492T1 (de) Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60028538D1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
ATE279401T1 (de) Verbindungen und verfahren zur behandlung von asthma, allergie und entzündlichen erkrankungen
EP1117395A4 (de) Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
NO20015673L (no) IL6RIL6 kimaere for behandlingen av nevrodegenerative sykdommer
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
ATE290866T1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties